Anti-2019-nCoV(S1) – 2 (H4) antibody

Reference: PTXCOV-A514
size

100µg

Brand

Product type

Clonality

Product nameAnti-2019-nCoV(S1) - 2 (H4) antibody
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity95%
Buffer25 mM Tris-HCl pH 7.5, 5 mM NaCl
FormLiquid
Delivery conditionBlue ice (+4°C)
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteogenix
ApplicationsELISA,WB
ReferencePTXCOV-A514
Related ProductsRBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant
NoteFor research use and in vitro diagnostic only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRecombinant spike protein - RBD domain for first type and variants (PX-COV-P046, PX-COV-P052)

Description of Anti-2019-nCoV(S1) - 2 (H4) antibody

About the product

Proteogenix has developed neutralizing antibodies against 2019-nCOV (as named by WHO when SARS-CoV-2 begun to spread). The Anti-2019-nCoV(S1)- 2(H4) antibody is an IgG1 isotype, especially targeting the S1 part of the Spike protein. This product is a human-origin monoclonal antibody expressed in a mammalian system, which has been validated in binding assays and infection assays. The molecular weight is 150 kDa.

About Spike : the target

The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Every of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. The antibody H4, blocks the RBD of the viral spike protein from binding to the cellular receptor, ACE2. This antibody is completely competitive with ACE2 for binding to RBD. It can bind simultaneously with the Anti-2019-nCoV(S1) – 1 (B38) antibody as these two antibodies are binding RBD in a different site.
Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic. This product is suitable in all immunological methods. Research use only.

SDS-PAGE for Anti-2019-nCoV(S1) - 2 (H4) antibody

Anti-2019-nCoV(S1) - 2 (H4) antibody, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Anti-2019-nCoV(S1) – 2 (H4) antibody”

Your email address will not be published. Required fields are marked *

Related products

RBD Domain
Antigen

RBD Domain

PX-COV-P046 250€
RBD-Fc
Antigen

RBD-Fc

PX-COV-P047 250€
SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant
Antigen

SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant

PX-COV-P052 250€
SARS-CoV-2 RBD of Spike protein, K417N, E484K, N501Y – B.1.351 lineage – SA Beta Variant
Antigen

SARS-CoV-2 RBD of Spike protein, K417N, E484K, N501Y – B.1.351 lineage – SA Beta Variant

PX-COV-P053 250€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products